Insider Buying: Harpoon Therapeutics Inc (HARP) Insider Acquires 1,000 Shares of Stock

Share on StockTwits

Harpoon Therapeutics Inc (NASDAQ:HARP) insider Gerald Phd Mcmahon purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was acquired at an average price of $10.16 per share, with a total value of $10,160.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Gerald Phd Mcmahon also recently made the following trade(s):

  • On Wednesday, May 8th, Gerald Phd Mcmahon purchased 1,000 shares of Harpoon Therapeutics stock. The stock was acquired at an average price of $10.56 per share, with a total value of $10,560.00.
  • On Friday, May 3rd, Gerald Phd Mcmahon purchased 1,000 shares of Harpoon Therapeutics stock. The stock was acquired at an average price of $10.53 per share, with a total value of $10,530.00.

Harpoon Therapeutics stock traded up $0.81 during mid-day trading on Friday, reaching $11.46. 44,107 shares of the stock traded hands, compared to its average volume of 49,395. The stock has a market cap of $279.25 million and a PE ratio of -0.45. Harpoon Therapeutics Inc has a 12-month low of $9.07 and a 12-month high of $17.85.

Harpoon Therapeutics (NASDAQ:HARP) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($8.15) EPS for the quarter. The company had revenue of $1.06 million during the quarter, compared to the consensus estimate of $1.22 million. Equities research analysts anticipate that Harpoon Therapeutics Inc will post -2.78 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of HARP. New Leaf Venture Partners L.L.C. bought a new stake in shares of Harpoon Therapeutics during the first quarter valued at approximately $21,262,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Harpoon Therapeutics during the first quarter valued at approximately $286,000. Northern Trust Corp bought a new stake in shares of Harpoon Therapeutics during the first quarter valued at approximately $309,000. MPM Asset Management LLC bought a new stake in shares of Harpoon Therapeutics during the first quarter valued at approximately $39,796,000. Finally, Fosun International Ltd bought a new stake in shares of Harpoon Therapeutics during the first quarter valued at approximately $3,062,000. Institutional investors own 0.19% of the company’s stock.

Several research analysts have recently weighed in on HARP shares. Wedbush started coverage on Harpoon Therapeutics in a research note on Tuesday, March 5th. They issued an “outperform” rating and a $23.00 price target for the company. Canaccord Genuity started coverage on Harpoon Therapeutics in a research note on Tuesday, March 5th. They issued a “buy” rating and a $24.00 price target for the company. Svb Leerink restated an “outperform” rating on shares of Harpoon Therapeutics in a research note on Tuesday, March 5th. Robert W. Baird started coverage on Harpoon Therapeutics in a research note on Monday, April 22nd. They issued an “outperform” rating and a $25.00 price target for the company. Finally, Zacks Investment Research cut Harpoon Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $24.00.

ILLEGAL ACTIVITY WARNING: This article was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://weekherald.com/2019/05/17/insider-buying-harpoon-therapeutics-inc-harp-insider-acquires-1000-shares-of-stock.html.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Featured Story: Lock-Up Period Expiration

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.